Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors for Non-Small Cell Lung Cancer Diagnosis DOI Creative Commons
Dengyue Xu, Qingyun Jiang, Zhi Li

et al.

Sensors, Journal Year: 2024, Volume and Issue: 24(24), P. 7899 - 7899

Published: Dec. 11, 2024

Non-small cell lung cancer (NSCLC) is the predominant form of and poses a significant public health challenge. Early detection crucial for improving patient outcomes, with serum biomarkers such as carcinoembryonic antigen (CEA), squamous carcinoma (SCCAg), cytokeratin fragment 19 (CYFRA 21-1) playing critical role in early screening pathological classification NSCLC. However, due to being mainly based on corresponding antibody binding reactions, existing technologies these have shortcomings complex operations, high false positive rates, costs. This study aimed develop new methods detecting CEA, SCCAg, CYFRA 21-1 assist diagnosis Affinity peptides 21-1, respectively, were screened by phage display technology, peptides’ affinities determined enzyme-linked immunosorbent assay biolayer interferometry. Peptides affinity then integrated domains into biosensors fusing them circularly permuted fluorescent proteins (cpFPs) through genetic coding. The resulting biosensors, C4 biosensor S1 Y3 demonstrated robust sensitivity specificity even at concentrations low 1 ng/mL their respective tumor markers. When applied clinical samples recalibrated upper limit normal concentrations, exhibited enhanced NSCLC diagnosis. introduced innovative providing highly sensitive, specific, rapid, cost-effective diagnostic alternative that could significantly improve rates.

Language: Английский

Enhanced stability of anthocyanins and phages by titanium dioxide-loaded cyclodextrin-metal organic frameworks: application as a cherry tomato preservative DOI
Jiagang Deng, Hui Shi

Food Bioscience, Journal Year: 2025, Volume and Issue: unknown, P. 106280 - 106280

Published: March 1, 2025

Language: Английский

Citations

1
Trends in the research and development of peptide drug conjugates: artificial intelligence aided design DOI Creative Commons

Donge Zhang,

Tong He, Tianyi Shi

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 27, 2025

Peptide-drug conjugates (PDCs) represent an emerging class of targeted therapeutic agents that consist small molecular drugs coupled to multifunctional peptides through cleavable or non-cleavable linkers. The principal advantage PDCs lies in their capacity deliver diseased tissues at increased local concentrations, thereby reducing toxicity and mitigating adverse effects by limiting damage non-diseased tissues. Despite the increasing number being developed for various diseases, advancements remain relatively slow due several development constraints, which include limited available linkers, narrow applications, incomplete evaluation information platforms PDCs. Marked recent Nobel Prize awarded artificial intelligence (AI) de novo protein design "protein structure prediction," AI is playing increasingly important role drug discovery development. In this review, we summarize developments limitations PDCs, highlights potential revolutionizing PDC.

Language: Английский

Citations

0
Microfluidics, an effective tool for supporting phage display-A review DOI
Liang Li, Hang Yuan,

Qin Li

et al.

Analytica Chimica Acta, Journal Year: 2024, Volume and Issue: 1326, P. 342978 - 342978

Published: July 15, 2024

Language: Английский

Citations

0
Engineered M13-Derived Bacteriophages Capable of Gold Nanoparticle Synthesis and Nanogold Manipulations DOI Open Access
Joanna Karczewska-Golec, Kamila Sadowska, Piotr Golec

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11222 - 11222

Published: Oct. 18, 2024

For years, gold nanoparticles (AuNPs) have been widely used in medicine and industry. Although various experimental procedures reported for their preparation manipulation, none of them is optimal all purposes. In this work, we engineered the N-terminus pIII minor coat protein bacteriophage (phage) M13 to expose a novel HLYLNTASTHLG peptide that effectively specifically binds gold. addition binding gold, phage could synthesize spherical AuNPs 20 nm other sizes depending on reaction conditions, aggregate them, precipitate from colloid, as revealed by transmission electron microscopy (TEM), atomic force (AFM), scanning (SEM), well ultraviolet–visible (UV–vis) Fourier-transform infrared (FTIR) spectroscopic methods. We demonstrated exposing foreign selected phage-displayed library may serve sustainable molecular factory both synthesis subsequent overnight ions at room temperature neutral pH absence strong reducing agents, such commonly NaBH4. Taken together, results suggest potential applicability new, vitro-identified gold-binding diverse biomimetic manipulations.

Language: Английский

Citations

0
Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors for Non-Small Cell Lung Cancer Diagnosis DOI Creative Commons
Dengyue Xu, Qingyun Jiang, Zhi Li

et al.

Sensors, Journal Year: 2024, Volume and Issue: 24(24), P. 7899 - 7899

Published: Dec. 11, 2024

Non-small cell lung cancer (NSCLC) is the predominant form of and poses a significant public health challenge. Early detection crucial for improving patient outcomes, with serum biomarkers such as carcinoembryonic antigen (CEA), squamous carcinoma (SCCAg), cytokeratin fragment 19 (CYFRA 21-1) playing critical role in early screening pathological classification NSCLC. However, due to being mainly based on corresponding antibody binding reactions, existing technologies these have shortcomings complex operations, high false positive rates, costs. This study aimed develop new methods detecting CEA, SCCAg, CYFRA 21-1 assist diagnosis Affinity peptides 21-1, respectively, were screened by phage display technology, peptides’ affinities determined enzyme-linked immunosorbent assay biolayer interferometry. Peptides affinity then integrated domains into biosensors fusing them circularly permuted fluorescent proteins (cpFPs) through genetic coding. The resulting biosensors, C4 biosensor S1 Y3 demonstrated robust sensitivity specificity even at concentrations low 1 ng/mL their respective tumor markers. When applied clinical samples recalibrated upper limit normal concentrations, exhibited enhanced NSCLC diagnosis. introduced innovative providing highly sensitive, specific, rapid, cost-effective diagnostic alternative that could significantly improve rates.

Language: Английский

Citations

0